Improving access to HIV prevention services in Kenya
Simplifying PrEP delivery: One-stop service pathway to improve PrEP care efficiency and continuation in Kenya
This study is testing a new way to make it easier for people in Kenya to get HIV prevention medication called PrEP by combining all the services they need into one visit at public health clinics, so they spend less time waiting and can start using PrEP more easily.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10873193 on NIH RePORTER |
What this research studies
This research aims to enhance the delivery of pre-exposure prophylaxis (PrEP) for HIV prevention by creating a one-stop service model in public health clinics in Kenya. The approach focuses on integrating all necessary services, such as testing and counseling, into a single visit to reduce wait times and improve patient experience. By addressing barriers like lengthy clinic visits and multiple appointments, the study seeks to increase the number of individuals who can access and continue using PrEP effectively. The methodology includes a cluster-randomized trial to evaluate the efficiency and acceptability of this new service model.
Who could benefit from this research
Good fit: Ideal candidates for this research are HIV-negative individuals in Kenya who are at high risk of HIV exposure and are seeking preventive measures.
Not a fit: Patients who are already HIV-positive or those who do not have access to the participating clinics may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve access to HIV prevention services, leading to higher rates of PrEP uptake and adherence among at-risk populations.
How similar studies have performed: Previous research has shown success with similar integrated service delivery models, indicating that this approach is both feasible and acceptable to patients.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Mugwanya, Kenneth Kiggundu — University of Washington
- Study coordinator: Mugwanya, Kenneth Kiggundu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.